Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Catalent announced the completion of a $3.2 million expansion program at its consumer health manufacturing facilities in Strathroy, Canada and Sorocaba, Brazil.
read more
Based upon its collaborative work with three pharmaceutical companies, PRISYM ID has launched an update to its flagship software solution for clinical supplies labeling.
read more
Catalent has completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan.
read more
Freyr has announced the launch of a web platform for Covid-19 driven with real-time information for manufacturers.
read more
Cambrex announced it is investing $3.6 million at its Karlskoga, Sweden facility to increase flexible drug substance manufacturing capacity.
read more
Lonza has announced additional investments in its global particle engineering network for expanded capacity and specialized capabilities.
read more
ADMA Biologics announced the commencement of operations and initiation of collections at its newest ADMA BioCenters plasma collection facility located in Knoxville, TN.
read more
Sharps Compliance announced the appointment of Adrian W. Burke as Senior Vice President of Operations.
read more
Mission has raised $15m in equity investment. The round was led by existing investor Pfizer Ventures, the venture capital arm of Pfizer.
read more
Eremid Research Services has been established as the new name for the commercial arm of the 501(c)(3) non-profit, research organization - DHMRI.
read more
Turning Point Therapeutics and Zai Lab announced an exclusive license agreement for the development and commercialization of Turning Point’s lead drug candidate, repotrectinib, in Greater China, which includes mainland China, Hong Kong, Macau and ...
read more
Vetter and Rentschler Biopharma have announced their strategic collaboration, to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain.
read more
Anixa Biosciences and OntoChem have completed the initial in silico screening process of their drug discovery program and have identified an additional specific compound, as well as multiple analogs, that could function as inhibitors of the main ...
read more
The FDA is alerting clinical laboratory staff and health care providers of an increased risk of a false positive result with BD SARS-CoV-2 Reagents for the BD Max System test.
read more
Lipidor announced an agreement with Cadila Pharmaceuticals to conduct a Phase III study for Lipidor's drug candidate AKP-02.
read more